Bladder cancer trials in France

In France 70 Also abroad 625

70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)
Where
Avignon, Dijon, Lille, Montpellier, Paris, Rennes, Rouen, Saint-Cloud, Saint-Herblain, Toulon, Villeurbanne
Age
18 years and over
People
120
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT07043543
Phase 3Not yet taking people in France
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
Where
Angers, Bordeaux, Brest, Clermont Ferrand Cedex1, Nantes Cedex 2, Paris, Rennes Cedex, Saint-Herblain Cedex, Strasbourg Cedex 2, Suresnes, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
142 worldwide
Run by
Systimmune Inc.
See details and how to join2026-527617-29-00 · EU 2026-527617-29-00
Phase 1Taking people
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Where
Paris, Villejuif
Age
18 years and over
People
294 worldwide
Run by
Pfizer
See details and how to joinNCT07206225 · EU 2025-521756-39-00
Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
Bordeaux, Lyon, Villejuif
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Where
Lille, Limoges, Lyon, Marseille, Paris, Quint-Fonsegrives, Rennes, Toulouse, Villejuif
Age
18 years and over
People
641 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06319820
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Marseille, Paris, Paris Cedex 18, Quint-Fonsegrives, Saint-Grégoire, Villejuif
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
Phase 3Taking people
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Where
Amiens Cedex 1, Bordeaux, Brest, Clermont Ferrand Cedex1, Creteil Cedex, Dijon, Lyon, Nice Cedex 2, Nimes Cedex 9, Paris, Rennes Cedex, Villejuif
Age
18 years and over
People
590 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00
Phase 2Taking people
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Where
Bordeaux Cedex, Lille Cedex, Paris, Saint-Etienne
Age
18 years and over
People
285 worldwide
Run by
Tyra Biosciences, Inc
See details and how to joinNCT07265947 · EU 2025-523539-20-00
Phase 2Taking people
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Where
Cedex Lyon 08, Paris, Rennes, Strasbourg, Suresnes, Toulouse, Villejuif
Age
18 years and over
People
240 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806
Phase 3Taking people
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Where
Bordeaux, Clermont-Ferrand, Lyon Cedex 03, Nantes, Nimes Cedex 9, Paris Cedex 13, Paris Cedex 18, Pierre-Bénite, Rouen Cedex, Saint-Priest-en-Jarez, Toulouse Cedex 9
Age
18 years and over
People
454 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00
Phase 3Taking people
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Where
Bordeaux, Clermont Ferrand Cedex 1, Lyon Cedex 03, Nantes, Nimes Cedex 9, Paris Cedex 13, Paris Cedex 18, Pierre-Bénite, Rennes, Saint-Priest-en-Jarez, Toulouse Cedex 9
Age
18 years and over
People
250 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06545955 · EU 2024-512177-27-01
Phase 2/3Taking people
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
Where
Amiens, Angers, Bordeaux, Bordeaux Cedex, Brest, Caen Cedex 5, Calais, Clermont Ferrand Cedex1, Creteil, Grenoble Cedex 9, La Chaussee St Victor, La Roche Sur Yon Cedex 9, Le Mans, Lyon, Marseille, Montpellier, Montpellier Cedex 5, Nantes Cedex 2, Nimes Cedex 9, Paris, Pierre-Bénite, Poitiers, Quint-Fonsegrives, Reims, Saint-Herblain Cedex, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
343 worldwide
Run by
Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00 · EU 2024-516906-47-00
Phase 1/2Taking people
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Where
Villejuif
Age
18 years and over
People
45 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07222488 · EU 2025-520467-40-00
Phase 3Taking people
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Where
Lille, Nîmes, Paris, Villejuif
Age
18 years and over
People
390 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156 · EU 2026-525612-34-00
Phase 2Taking people
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Where
Amiens, Marseille, Saint-Priest-en-Jarez
Age
18 years and over
People
90 worldwide
Run by
Tyra Biosciences, Inc
See details and how to joinNCT06995677 · EU 2025-521277-14-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Not yet taking people in France
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Lyon, Marseille
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 2Not yet taking people in France
MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.
Where
Bordeaux, Lyon, Nice Cedex 2, Paris, Toulouse, Villejuif
Age
18 years and over
People
200
Run by
Centre Leon Berard
See details and how to join2025-522058-38-00 · EU 2025-522058-38-00
Phase 2Taking people
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Where
Angers, Bordeaux, Bordeaux Cedex, Chambray-lès-Tours, Dijon, Lille, Lyon, Marseille, Montpellier, Nice Cedex 2, Nîmes, Paris, Pierre-Bénite, Poitiers, Quint-Fonsegrives, Rennes Cedex, Rouen Cedex, Strasbourg Cedex 2, Suresnes
Age
18 years and over
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT06960577 · EU 2024-519246-75-01
Phase 3Taking people
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Angers, Bordeaux, Brest, Caen, Lille, Lyon Cedex08, Marseille, Nîmes, Pierre-Bénite, Toulouse, Villejuif
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
No phaseTaking people
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
Where
Boulogne-Billancourt, Paris
Age
18 years and over
People
100
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07739121
Phase 1/2Taking people
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Where
Bordeaux
Age
18 years and over
People
55 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07232602 · EU 2025-522253-19-00